Evidence map›Paper›PMID 33673382›Full record

ArticlePharmaceutics2021

Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model.

Bassel Akache, Gerard Agbayani, Felicity C Stark, Yimei Jia, Renu Dudani, Blair A Harrison, Lise Deschatelets, Vandana Chandan, Edmond Lam, Usha D Hemraz and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Bassel AkacheHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Gerard AgbayaniHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Felicity C StarkHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.ORCID 0000-0002-7547-8493
Yimei JiaHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Renu DudaniHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Blair A HarrisonHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Lise DeschateletsHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Vandana ChandanHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Edmond LamAquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada.
Usha D HemrazAquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada.
Sophie RégnierAquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada.
Lakshmi KrishnanHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.
Michael J McCluskieHuman Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada.ORCID 0000-0001-5538-1363
National Research Council Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a leading cause of morbidity and mortality worldwide. While novel treatments have improved survival outcomes for some patients, new treatment modalities/platforms are needed to combat a wider variety of tumor types. Cancer vaccines harness the power of the immune system to generate targeted tumor-specific immune responses. Liposomes composed of glycolipids derived from archaea (i.e., archaeosomes) have been shown to be potent adjuvants, inducing robust, long-lasting humoral and cell-mediated immune responses to a variety of antigens. Herein, we evaluated the ability of archaeosomes composed of sulfated lactosyl archaeol (SLA), a semi-synthetic archaeal glycolipid, to enhance the immunogenicity of a synthetic long peptide-based vaccine formulation containing the dominant CD8

Indexed as

adjuvantarchaeosomecancerglycolipidPoly(I:C)SLAsynthetic long peptidevaccine

Identifiers

PMID33673382
PMCPMC7918940
OpenAlexW3131214209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.